Surveillance data demonstrate that the majority of gram-positive bacterial isolates obtained in the intensive care unit (ICU) setting are staphylococci and enterococci. Staphylococci, mainly Staphylococcus aureus and coagulase-negative staphylococci, compose the majority of clinical isolates. Data from 25 North American ICUs reported methicillin-resistant Saureus (MRSA) in more than 50% of the Saureus organisms isolated mainly from a respiratory source. In addition to MRSA, Saureus with reduced susceptibility to vancomycin has been reported. Enterococci are typically considered opportunistic pathogens, infecting immunocompromised hosts. Resistance of enterococci to vancomycin, along with the newer gram-positive antimicrobials, is an increasing problem. Investigators have demonstrated that nearly 30% of enterococci isolated in the ICU are resistant to vancomycin. The high level of resistance and limited therapeutic options make treating resistant gram-positive organisms such as MRSA and vancomycin-resistant enterococci particularly problematic. While vancomycin has long been considered the gold standard for the treatment of resistant gram-positive infections, newer agents (eg, quinupristin-dalfopristin, linezolid, and daptomycin) offer therapeutic alternatives.
Fluit AC, Verhoef J, Schmitz FJ, and the European SENTRY Participants. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 254 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis. 2001;20:617-625.
2.
Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit: a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob. 2004;3:14.
3.
Centers for Disease Control and Prevention. CDC 1992 public health focus: surveillance, prevention and control of nosocomial infections. MMWR Morb Mortal Wkly Rep. 1992;41:783-787.
4.
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents. 2004;24:111-118.
5.
Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary January 1992 to June 2003, issued August 2003. Am J Infect Control. 2003;31:481-498.
6.
Lowry FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
Jevons MP. Celbenin-resistant staphylococci. Br Med J. 1961;1:124-125.
9.
Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureusTrends Microbiol. 2001;9:486-493.
10.
Clark NM, Hershberger E, Zervos MJ, Lynch JP. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Current Opin Crit Care. 2003;9:403-412.
11.
Rennie RP, Jones RN, Mutnick AH, and the SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis. 2003;45:287-293.
12.
Fridkin SK, Steward CD, Edwards JR, et al.Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Clin Infect Dis. 1999;29:245-252.
13.
Wisplinghoff H, Bischoff T, Tallent SM, et al.Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
14.
Edmond MB, Wallance SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in the United States: a three-year analysis. Clin Infect Dis. 1999;29:239-244.
Staphylococcus aureus with reduced susceptibility to vancomycin—Illinois, 1999. MMWR Morb Mortal Wkly Rep. 2000;48:1165-1167.
17.
CDC public health dispatch: vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:902.
18.
National Committee for Clinical Laboratory Standards (2000) methods for 5th ed. Approved standard. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19.
Ang JY, Ezike E, Asmar BL. Antibacterial resistance. Indian J Pediatr. 2004;71:229-239.
20.
Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004;39:539-545.
21.
Rice LB. Emergence of vancomycin-resistant enterococci. Emerg Infect Dis. 2001;7:183-187.
22.
Low DE, Keller N, Barth A, et al.Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(suppl 2):S133-S145.
23.
Shepard BD, Gilmore MS. Antibiotic-resistant enterococci: the mechanisms and dynamics of drug introduction and resistance. Microbes Infect. 2002;4:215-224.
24.
Mathai D, Jones RN, Pfaller MA, SENTRY Participant Group North America. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis. 2001;40:129-136.
25.
Diekema DJ, Pfaller MA, Jones RN, and the SENTRY Participants Group. Int J Antimicob Agents. 2002;20:412-418.
26.
Wilhelm MP, Estes L. Symposium on antimicrobial agents—Part XII: vancomycin. Mayo Clin Proc. 1999;74:928-935.
Red Book and Updates. Montvale, NJ: Medical Economics; 2004.
29.
Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of daptomycin, linezolid and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist. 2003;9:389-393.
30.
Cha R, Brown W, Rybak M. Bactericidal activities of daptomycin, quinupristin-dalfoprisitin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocaridal vegetations. Antimicrob Agents Chemother. 2003;47:3960-3963.
31.
Eliopoulos G.Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473-481.
32.
Synercid [package insert]. Bristol, TN: Monarch Pharmaceuticals, Inc; July 2003.
33.
Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs. 1996;52:406-415.
34.
Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis. 2004;38:92-98.
35.
Raad I, Hachem R, Hanna H, et al.Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicob Chemother. 2004;53:646-649.
36.
Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23:113-119.
Moellering, R.Linezolid: the first oxazolidinone antimicrobial. AnnInternMed. 2003;138:135-142.
39.
Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22:91-97.
40.
Brier ME, Stalker DJ, Aronoff GR, et al.Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775-2780.
41.
MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother. 2003;51(suppl S2) ii17-ii25.
42.
Slatter JG, Stalker DJ, Feenstra KL, et al.Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:1136-1145.
43.
Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45:1843-1846.
44.
Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475-1480.
45.
Villani P, Regazzi MB, Marubbi F, et al.Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections [letter]. Antimicrob Agents Chemother. 2002;46:936-937.
46.
Kutscha-Lissberg F, Hebler U, Muhr G, Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47:3964-3966.
47.
Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother. 2002;50:747-750.
48.
Nasraway SA, Shorr AF, Kuter DJ, O’Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis. 2003;11:1609-1616.
49.
Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy. 2004;24:41-57.
50.
Sun H, Kuti J, Nicolau D. Daptomycin. Formulary. 2003;38:634-645.
Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-68.
53.
Cubicin [package insert]. Lexington, Mass: Cubist Pharmaceuticals, Inc; September 2003.
54.
Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis. 2003;47:539-546.
55.
Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994-999.
56.
Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-1323.
Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, and the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-1681.
59.
Rello J, Paiva JA, Baraibar J, et al.International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest. 2001;120:955-970.
60.
Rubenstein E, Cammarata S, Oliphant T, Wunderink R, Linezolid Nosocomial Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412.
61.
Hierholzer WJ, Garner JS, Adams AB, et al.Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC): The Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1995;23:87-94.
62.
Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980-992.
63.
Zack JE, Garrison T, Trovillion E, et al.Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med. 2002;30:2407-2412.
64.
Mermel L, Farr MD, Sheretz R, et al.Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249-1272.
65.
Byers KE, Adal KA, Anglim AM, Farr BM. Case fatality rate for catheter-related bloodstream infections (CRBSI): a meta-analysis. Paper presented at: the 5th Annual Meeting of the Society for Healthcare Epidemiology of America; April 2-4, 1995; San Diego, Calif.
66.
Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis. 2003;365:675-676.
67.
Pistella E, Campanile F, Bongiorno D, et al.Successful treatment of disseminated cerebritis complication methicillin-resistant Staphylococcus aureus endocarditis unresponsive to vancomycin with linezolid. Scand J Infect Dis. 2004;36:222-225.
68.
Bayer AS, Scheld WM. Endocarditis and intravascular infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed.Philadelphia, Pa: Churchill Livingstone; 2000:857-902.
69.
Moreillon P, Que Y. Infective endocarditis. Lancet. 2004;363:139-149.
70.
Babcoci HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis. 2001;32:1373-1375.
71.
Codon RE. Micorbiology of intraabdominal infection and contamination. Eur J Surg Suppl. 1996;576:9-12.
72.
Bohen JMA. Antibiotic therapy of abdominal infection. World J Surg. 1998;22:152-157.
73.
Pelletier SJ, Raymond DP, Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Outcome analysis of intraabdominal infection with resistant gram-positive organisms. Surg Infect. 2002;3:11-19.
74.
Solomkin JS, Mazuski JE, Baron EJ, et al.Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997-1005.
